This result is critical for CLL patients with mutant p53 (or even a 17p deletion), as they indicate that ibrutinib does not require a fully functional p53 response for its efficacy, and thus primarily exerts its effects through mechanisms outside the p53 pathway. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.